By utilizing an orthotopic cancer model with the MOC2 cell line injected into WT and Pik3cg−/− mice, we have demonstrated that PI3K p110γ modulates host immune activity in a manner that likely potentiates the efficacy of anti-PD-L1 immunotherapy against HNSCC. The gene discussed is CD274; the disease is cancer.